Ugrás a tartalomhoz

Genetika és genomika

Falus András, László Valéria, Tóth Sára, Oberfrank Ferenc, Pap Erna, Dr. Szalai Csaba (2014)

Typotex Kiadó



[13.4] Erdelyi DJ, Kamory E, Zalka A, Semsei AF, Csokay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galantai I, Fekete G, Falus A, Szalai C, Kovacs GT. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell Immunol. 2006 Dec; 244(2):121–4.

[13.5] Erdélyi DJ, Kámory E, Csókay B, Andrikovics H, Tordai A, Kiss C, Félné-Semsei Á, Janszky I, Zalka A, Fekete G, Falus A, Kovács GT, Szalai C. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J. 2008 8: 321–327.

[13.6] Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT. ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int. 2011 Sep 20. [Epub ahead of print] PubMed PMID: 21929509.

[13.7] Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010 Mar; 11(3):439–48.

[13.8] Gasche Y, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004 Dec 30; 351(27):2827–31.

[13.10] Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther. 2008 Dec; 10(6):555–61.

[13.11] Mangravite LM,et al.. Clinical implications of pharmacogenomics of statin treatment The Pharmacogenomics Journal (2006) 6, 360–374.

[13.13] Rosenson RS. A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN. Curr Atheroscler Rep. 2009 May; 11(3):161–4.

[13.14] Wojczynski MK, et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J Lipid Res. 2010 Nov; 51(11):3316–23.

[13.15] Liggett, S.B.: Assay Drug Dev Technol. Polymorphisms of adrenergic receptors: variations on a theme. 2003; 1: 317–326.

[13.16] Liggett, S.B.: Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology. 2000; 61:167–173.

[13.17] Martinez, F.D., et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997, 100, 3184–3188.

[13.18] McGraw, D.W., Forbes, S.L., Kramer, L.A., Liggett, S.B.: Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998, 102, 1927–1932.

[13.19] Israel, E., Drazen, J.M., Liggett, S.B, et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol. 2001, 124, 183–186.

[13.20] Lazarus, S.C., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001, 285, 2583–2593.

[13.21] Israel, E. et al. Use of regularly scheduled albuterols treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004, 364, 1505–1512.

[13.22] Drazen, J.M., et al. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999, 340, 197–206.

[13.23] Drazen, J.M., et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999; 22, 168–170.

[13.24] Sampson, A.P., et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000, 55, Suppl 2:S28–31.

[13.25] Sanak M, et al. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 2000, 23, 290–296.

[13.26] Sanak, M., et al. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 1997, 350, 1599–1600.

[13.27] Whelan, G.J., et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol. 2003, 36, 413–420.

[13.28] Hawkins GA, et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol. 2009 Jun; 123(6):1376–83.e7.

[13.29] Tantisira, K.G., et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet. 2005; 14: 1671–1677.

[13.30] Tantisira, K.G., et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004;101:18099–18104.

[13.31] Tantisira, K.G., et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet. 2005, 14, 1671–1677.

[13.32] Tantisira KG, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011 Sep 29; 365(13):1173–83.

[13.33] Palmer, L.J., et al. Pharmacogenetics of asthma. Am J Respir Crit Care Med.. 2002,15, 861–866.

[13.34] Distefano JK, Watanabe RM. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel). 2010 Aug 1; 3(8):2610–2646.

[13.35] Konoshita T; Genomic Disease Outcome Consortium (G-DOC) Study Investigators. Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the Renin-Angiotensin system. Curr Hypertens Rep. 2011 Oct; 13(5):356–61.

[13.36] Manunta P, et al. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension. 2008 Aug; 52(2):366–72.

[13.37] Turner ST, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359–65.

[13.38] Chung CM, et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. 2010 Dec; 10(6):537–44.

[13.39] Corvol JC, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol. 2011 Jan; 69(1):111–8.

[13.40] Arbouw ME, et al. Novel insights in pharmacogenetics of drug response in Parkinson's disease. Pharmacogenomics. 2010 Feb; 11(2):127–9.

[13.41] Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000 Jun 15; 405(6788):857–65.